MCK vs MDLN: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
MCK is the larger of the two ($117.14B market cap): the incumbent the market prices for continued execution (19.84x forward earnings, beta 0.28). MDLN is the smaller challenger ($45.11B), priced similarly on forward earnings (21.36x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
MCK vs MDLN: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | MCK | MDLN | What it tells you |
|---|---|---|---|
| Market cap | $117.14B | $45.11B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 19.84 | 21.36 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 26.93 | 83.82 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Price vs 52-week range | 92% of range | 11% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how MCK and MDLN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MCK and MDLN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MCK and MDLN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does McKesson Corporation (MCK) do?
McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the "Big Three" US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and Cardinal Health that together handle the large majority of prescription drugs sold in the country. In fiscal 2026 (ended March 2026) the company reported roughly $403 billion in revenue, and trailing revenue has since reached about $411 billion, the bulk of it from its North American Pharmaceutical segment, which sources, warehouses, and delivers branded, generic, and specialty medicines to pharmacies, health systems, and providers. Because distribution is a scale game with very low margins, McKesson competes on logistics efficiency, breadth of contracts, and reliability rather than pricing power on the drugs themselves.
What does Medline (MDLN) do?
Medline makes and distributes the unglamorous consumables that hospitals, surgery centers, physician offices, and nursing homes go through every single day: gloves, gowns, surgical kits, wound care, incontinence products, exam-room supplies, and diagnostics. It reports in two segments. Medline Brand covers products the company manufactures and sells under its own label (surgical solutions, front-line care, laboratory and diagnostics), and it carries the better margin. Supply Chain Solutions distributes third-party manufacturers' brands and runs the prime-vendor logistics contracts that put Medline trucks on a health system's loading dock several times a week. Roughly 90 percent of revenue is domestic. The company employs about 45,000 people and is headquartered in Northfield, Illinois.
MCK vs MDLN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- MCK drivers: Defensive, volume-driven distribution core; Specialty and oncology services mix-shift.
- MDLN drivers: Prime-vendor contracts in Supply Chain Solutions; Mix shift toward Medline Brand products.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results. For MDLN, the clearest near-term risk is regulatory.
MCK or MDLN: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MCK if you believe its drivers more; MDLN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MCK and MDLN guides.
MCK vs MDLN: the full fundamentals
MCK. All figures are approximate and tied to the asOf date; verify live numbers before acting. McKesson reports on a fiscal year ending in March, so the June 2026 quarter is fiscal Q1 2027. Revenue multiples mean little here (about 0.28 times sales); at about $1,004 a share the stock trades near 27 times trailing GAAP earnings and 20 times forward estimates, with analysts modeling adjusted EPS of about $44.66 for fiscal 2027 and $50.63 for fiscal 2028.
MDLN. Trailing GAAP P/E looks extreme (Yahoo Finance shows about 92x) because trailing net income is depressed by the Tracy fire, quality remediation spend, and post-IPO charges and because pre-IPO share counts distort per-share math, which is why the market watches adjusted EBITDA and forward earnings instead; on consensus 2026-2027 EPS the stock trades near 23x. Full-year adjusted EBITDA guidance was cut to $3.3 to $3.4 billion in August 2026 even as organic growth guidance went up to 9 to 10 percent, and the shares fell roughly 13 percent on the day. Consensus for the November 4, 2026 report is about $0.35 of EPS on $7.72 billion of revenue. Medline does not pay a dividend.
Headline figures (approximate, October 2026): MCK shows revenue (ttm) ~$411 billion (+7.7% YoY latest quarter), margin profile ~3.6% gross, ~1.35% operating, ~1.1% net (distribution dominates revenue), net income (ttm) ~$4.6 billion, adjusted eps (fiscal q1 2027) ~$9.93 vs ~$9.54 est.; MDLN shows revenue (ttm) ~$29.9B, up ~12%, q2 2026 net sales ~$7.7B, up ~11.6%, gross margin (ttm) ~25%, net income (ttm) ~$701M, ~2.3% net margin.
The bottom line: MCK vs MDLN
MCK and MDLN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MCK and MDLN exposure against your real portfolio. It is not an investment adviser.
Wondering how MCK or MDLN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in McKesson Corporation with AI
Connect the broker you already use and ask Walnut's AI how MCK fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between MCK and MDLN?
+
McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the "Big Three" US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and Cardinal Health that together handle the large majority of prescription drugs sold in the country. Medline makes and distributes the unglamorous consumables that hospitals, surgery centers, physician offices, and nursing homes go through every single day: gloves, gowns, surgical kits, wound care, incontinence products, exam-room supplies, and diagnostics. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is MCK or MDLN the better stock?
+
Neither is universally better. MCK is the larger incumbent; MDLN is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, MCK or MDLN?
+
On forward P/E (as of November 2026), MCK trades at 19.84x and MDLN at 21.36x, so MCK is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both MCK and MDLN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of MCK vs MDLN?
+
MCK: The central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results. Customer concentration is real, with a few very large retail-pharmacy customers representing a big share of revenue, giving those partners negotiating leverage. Drug-pricing politics and policy (Medicare negotiation, PBM reform, importation proposals) create ongoing regulatory uncertainty. McKesson also carries a legacy of multibillion-dollar opioid-distribution settlements, and future litigation or regulatory action remains a tail risk. Execution on the Medical-Surgical separation, on integrating oncology and specialty acquisitions, and on the Option Care Health partnership adds transition risk on top of the steady core. GAAP earnings can also swing well away from adjusted figures: GAAP net income was about $614 million in the June 2026 quarter versus about $1.68 billion in the March quarter. Valuation has stretched as well, with the shares up about 21% in three months to above $1,000 and trading near 27 times trailing GAAP earnings. MDLN: The clearest near-term risk is regulatory. As of late June 2026 Medline had received three FDA warning letters covering facilities in Northfield, Illinois, Glens Falls, New York, and Waukegan, Illinois, with the Waukegan letter calling certain drug products adulterated after Bacillus cereus turned up in finished product samples on nine separate occasions between June 2023 and August 2025. Remediation costs money, can interrupt supply from specific plants, and invites further inspection. Second, the net margin is thin enough (roughly 2 percent trailing) that operational shocks like the Tracy distribution center fire, which cost about $336 million before insurance in the first half with another $50 million to $100 million expected in the second, dominate reported earnings even when the underlying business is fine. Third, tariffs and freight costs pass through a global sourcing base with a lag, and the second quarter figure was flattered by about $243 million of tariff refunds that will not repeat. Fourth, hospital group purchasing organizations negotiate hard and Cardinal Health, McKesson, and Owens & Minor all want the same shelf space. Finally, Blackstone, Carlyle, and Hellman & Friedman still hold a large block and have already run one $3.6 billion secondary at $41 per share, and with the stock near $37 in mid-October 2026 that sale now sits above the market, so supply overhang is a live factor in how the shares trade. Several shareholder law firms announced investigations following the FDA disclosure. UBS trimmed its price target to $43 from $45 in September 2026 while keeping a buy rating, and the shares touched a 52-week low near $31.49 before rebounding.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell MCK or MDLN; figures are approximate and dated (as of November 2026). Verify current data before investing.